Literature DB >> 12234688

Structural and functional characterization of the human PAX7 5'-flanking regulatory region.

Yana V Syagailo1, Olga Okladnova, Ella Reimer, Marcus Grässle, Rainald Mössner, Stefan Gattenlöhner, Alexander Marx, Jobst Meyer, Klaus-Peter Lesch.   

Abstract

The human PAX7 gene is a member of the paired box containing gene family of transcription factors implicated in development of the skeletal muscle of the trunk and limbs as well as elements of the central nervous system. To understand the molecular mechanisms involved in its expression, we have localized the transcription start sites in adult skeletal muscle and functionally characterized the 5'-flanking regulatory region responsible for PAX7 expression in this tissue. The major transcription start was identified 664 bp upstream from the ATG codon using primer extension and 5'-rapid amplification of cDNA ends (5'-RACE). Analysis of the 5'-flanking sequence revealed the absence of a TATA-box and the presence of an inverted CCAAT-box. Several consensus sites for common transcriptional regulators including Oct-1, NF1, AP2, AP4, CREB, Sp1, Nkx2.5, and MyoD are present in the promoter region. To determine the sites critical for the function of the PAX7 promoter, a series of deletion fragments of the 5'-flanking region were cloned adjacent to luciferase reporter gene and expressed in RD, Cos-7 and JAR cell lines. The maximal promoter activity was achieved by a fragment extending from the position -403 to +373. No strong positive or negative regulatory elements were discovered by adding of further sequences (up to 2.97 kb). A polymorphic (CCT)(n) repeat sequence was found 107 bp upstream of the transcription initiation site. PCR-based systematic screening for length variations in 227 unrelated individuals of a Caucasian population showed a bimodal distribution of three alleles containing 8, 10 or 11 repeat units. When different variants of this PAX7 gene-linked polymorphic region (PAX7-LPR) were fused to a luciferase reporter gene and transfected into RD cells, the variant with 11 repeat units revealed higher transcriptional efficiency compared to the 8 or 10 repeat alleles.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12234688     DOI: 10.1016/s0378-1119(02)00798-9

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  6 in total

1.  A GAG trinucleotide-repeat polymorphism in the gene for glutathione biosynthetic enzyme, GCLC, affects gene expression through translation.

Authors:  Sailendra N Nichenametla; Philip Lazarus; John P Richie
Journal:  FASEB J       Date:  2011-03-28       Impact factor: 5.191

2.  Over-expression of the transcription factor, ZBP-89, leads to enhancement of the C2C12 myogenic program.

Authors:  Morgan Salmon; Gary K Owens; Zendra E Zehner
Journal:  Biochim Biophys Acta       Date:  2009-02-14

3.  Neuropathology and Cellular Pathogenesis of Spinocerebellar Ataxia Type 12.

Authors:  Elizabeth E O'Hearn; Hyon S Hwang; Susan E Holmes; Dobrila D Rudnicki; Daniel W Chung; Ana I Seixas; Rachael L Cohen; Christopher A Ross; John Q Trojanowski; Olga Pletnikova; Juan C Troncoso; Russell L Margolis
Journal:  Mov Disord       Date:  2015-09-04       Impact factor: 10.338

4.  Pax7 is regulated by cMyb during early neural crest development through a novel enhancer.

Authors:  Stephanie Vadasz; Jonathan Marquez; Maria Tulloch; Natalia A Shylo; Martín I García-Castro
Journal:  Development       Date:  2013-09       Impact factor: 6.868

5.  A polymorphic (GA/CT)n- SSR influences promoter activity of Tryptophan decarboxylase gene in Catharanthus roseus L. Don.

Authors:  Santosh Kumar; Sabhyata Bhatia
Journal:  Sci Rep       Date:  2016-09-13       Impact factor: 4.379

6.  A novel PAX7 10-bp indel variant modulates promoter activity, gene expression and contributes to different phenotypes of Chinese cattle.

Authors:  Yao Xu; Tao Shi; Yang Zhou; Mei Liu; Sebastian Klaus; Xianyong Lan; Chuzhao Lei; Hong Chen
Journal:  Sci Rep       Date:  2018-01-29       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.